Betaseron Articles
New York Stock Comment
27 May 1996
Biogen Sees First Launch Of MS Drug Avonex
27 May 1996
EMEA 1995-95: A Crucial Period of Transition
25 March 1996
BASF To Acquire Stake In Hokuriku
25 March 1996
US Clearance For Biogen's Avonex Expected Soon
18 March 1996
Revenues Surge At Chiron In 1995
18 March 1996
Israeli Drug Discount Plan For Pensioners
4 March 1996
Schering AG Optimistic About 1996
8 January 1996
Schering AG faces Shell lawsuit
8 January 1996
EU CPMP December Plenary Meeting
8 January 1996
No Drug Approval Lag, "At Least Not In The USA"
18 December 1995
New York Stock Comment
4 December 1995
...While Schering's Betaferon Is Cleared In The EU
4 December 1995
Biogen's Interferon Beta Nears US Approval
4 December 1995
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
MS: Hope, Expectations, And Disappointments
23 October 1995
UK NHS "Under Worst Attack For 50 Years"
9 October 1995
More Israeli Court Action Over MS Drug
11 September 1995
Five-Year IFN-1b Data In MS Published
21 August 1995
Flat Interim Results From Schering AG
14 August 1995
Interferon Sciences Targets MS
19 June 1995
Biogen Files For Avonex MS Drug In USA
29 May 1995
Biogen Files For Avonex MS Drug In USA
29 May 1995
NEW YORK STOCK COMMENT
22 May 1995
Eight-Year-Old Cephalon Integrates For Success
22 May 1995
European stock comment
15 May 1995
Schering AG Sees 1st Qtr Profits Downturn
8 May 1995
European STOCK COMMENT
24 April 1995
NEW YORK STOCK COMMENT
10 April 1995
Chiron Cutting Workforce
10 April 1995
Schering's Turnover Down But Betaseron Sales Surge
20 March 1995
ICN And A L Hit By Restructuring Charges
13 March 1995
NEW YORK STOCK COMMENT
20 February 1995
Schering AG Sales And Profits Surge
13 February 1995
Betaseron Is Schering's Most Successful Drug Ever
13 February 1995
European STOCK COMMENT
23 January 1995
Positive Patent News For Schering AG
23 January 1995
Polarization Concerns For Chemical/Drug Majors?
16 January 1995
...And Israel's Teva Recommended
2 January 1995
European Stock Comment
28 November 1994
World Immunology, Rheumatology Markets
28 November 1994
European Stock Comment
21 November 1994
Betaseron Sales Boost Schering's 9 Months
21 November 1994
Chiron Shares Soar On Ciba Stake Rumors
21 November 1994
NEW YORK STOCK COMMENT
14 November 1994
Mixed Quarterly Results From The USA
14 November 1994
Long-Term Data On Schering's Betaseron
31 October 1994
Phase III Results For Copolymer 1 Disappointing
17 October 1994
Phase III Results With Biogen's Interferon Beta
17 October 1994
Schering, Rentschler In Betaseron Deal
17 October 1994
Currency Impacts Schering AG's Earnings Growth
15 August 1994
Biogen's MS Drug On Market In 1st Half '95?
1 August 1994
European Stock Comment
25 July 1994
Confidence At Schering For 1994
25 July 1994
SCHERING SUBMITS FOR BETASERON IN EUROPE
6 June 1994
2nd DEOXYSPERGUALIN TRIAL DISAPPOINTS
6 June 1994
NEW YORK STOCK COMMENT
30 May 1994
NEW YORK STOCK COMMENT
23 May 1994
SCHERING AG 1ST QTR SALES UP 19%
16 May 1994
1ST QTR RESULTS MIXED FOR SMALLER US FIRMS
16 May 1994
GERMAN FIRMS' 1ST QTRS LOOK BETTER
9 May 1994
BUY RECOMMENDATION FOR TEVA STOCK
11 April 1994
CHIRON LOOKING FLAT AFTER BETASERON HIGH
11 April 1994
NEW THERAPIES FOR MULTIPLE SCLEROSIS
4 April 1994
SCHERING AG EXPECTS FLAT PROFITS IN 1994
21 March 1994
REVENUES COME IN FROM BETASERON AT CHIRON
14 March 1994
SCHERING AG SEES PROFITS DIP
14 February 1994
NEW STOCK COMMENT
14 February 1994
EUROPEAN STOCK COMMENT
31 January 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
BIOGEN CLAIMS FULL BETA INTERFERON PRODUCTION CAPACITY
24 January 1994
WORLD PRODUCT NEWS IN BRIEF
24 January 1994
EUROPEAN STOCK COMMENT
24 January 1994
UK BIOTECH STOCKS STARTING TO MATURE
13 December 1993
NEW YORK STOCK COMMENT
6 December 1993
SCHERING SAYS DRUG BUSINESS WILL GROW
22 November 1993
EUROPEAN STOCK COMMENT
25 October 1993
CHIRON REASSURES ON BETASERON
25 October 1993
EUROPEAN STOCK COMMENT
25 October 1993
NEW YORK STOCK COMMENT
4 October 1993
BIOTECH STOOCK VS CLINTON HEALTH REFORM
4 October 1993
PMA WARNING ON FUTURE OF BIOTECHNOLOGY
27 September 1993
ARES-SERONO WILL BENEFIT FROM MS MARKET
27 September 1993
BETASERON SUPPLIED BY LOTTERY
13 September 1993
BETASERON DISTRIBUTION
6 September 1993
CHIRON TO PRODUCE BETASERON
6 September 1993
SCHERING AG GETS ANALYSTS' UPGRADING
23 August 1993
EUROPEAN STOCK COMMENT
23 August 1993
BETASERON COSTS CAUSE CONCERN
23 August 1993
EUROPEAN STOCK COMMENT
16 August 1993
SCHERING AGSHARES SOAR
16 August 1993
GOOD 1993 FIRST HALF FOR SCHERING AG
16 August 1993
SCHERING'S BETASERON APPROVED IN USA
2 August 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
SCHERING AG ON THRESHOLD
12 July 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
FDA PANEL BACKS BERLEX DRUGS
7 June 1993
SCHERING AG TO EXPAND PHARMA DIV
31 May 1993
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
